PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-30.79%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-31.28%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-21.00%
Negative EPS growth while CRVO is at 5.64%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.22%
Negative diluted EPS growth while CRVO is at 5.64%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.78%
Share reduction more than 1.5x CRVO's 19.10%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
7.68%
Diluted share reduction more than 1.5x CRVO's 19.10%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Negative OCF growth while CRVO is at 17.52%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-4.24%
Negative FCF growth while CRVO is at 17.52%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Negative 10Y OCF/share CAGR while CRVO stands at 99.40%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
76.96%
5Y OCF/share CAGR at 75-90% of CRVO's 97.12%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
70.68%
3Y OCF/share CAGR at 75-90% of CRVO's 83.06%. Bill Ackman would press for improvements in margin or overhead to catch up.
-11609.25%
Negative 10Y net income/share CAGR while CRVO is at 99.62%. Joel Greenblatt sees a major red flag in long-term profit erosion.
81.05%
5Y net income/share CAGR at 75-90% of CRVO's 97.84%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
70.82%
3Y net income/share CAGR 75-90% of CRVO's 92.43%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
881.79%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-26.92%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-79.64%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-41.29%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-11.75%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
20.45%
R&D growth drastically higher vs. CRVO's 14.83%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
69.30%
SG&A growth well above CRVO's 20.77%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.